News articles about Evolus (NASDAQ:EOLS) have trended somewhat positive on Tuesday, according to Accern. The research group identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Evolus earned a news sentiment score of 0.07 on Accern’s scale. Accern also gave news coverage about the company an impact score of 46.9850836429331 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Shares of Evolus stock traded down $0.30 on Tuesday, hitting $7.71. 71,842 shares of the company’s stock were exchanged, compared to its average volume of 126,669. The stock has a market capitalization of $187.94 and a PE ratio of -28.56. Evolus has a 1 year low of $7.53 and a 1 year high of $12.97.
Evolus (NASDAQ:EOLS) last released its earnings results on Thursday, March 29th. The company reported $0.24 earnings per share for the quarter. equities research analysts expect that Evolus will post -2.1 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Evolus (EOLS) Given Daily Coverage Optimism Rating of 0.07” was published by Week Herald and is the sole property of of Week Herald. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://weekherald.com/2018/04/24/evolus-eols-getting-somewhat-favorable-media-coverage-analysis-shows.html.
Evolus, Inc provides medical aesthetic products for physicians and their patients in the United States. It offers DWP-450, an injectable 900 kilodalton botulinum toxin type A complex designed to address the needs of the facial aesthetics market. The company was founded in 2012 and is headquartered in Irvine, California.
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.